High-dose cyclophosphamide for graft-versus-host disease prevention

Current Opinion in Hematology

Volumn 17, Issue 6, 2010, Pages 493-499

  Luznik, Leo ^a   Jones, Richard J ^a   Fuchs, Ephraim J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

allogeneic blood or marrow transplantation; graft versus host disease; posttransplantation cyclophosphamide; transplantation tolerance

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENGRAFTMENT; EVENT FREE SURVIVAL; GRAFT VERSUS HOST REACTION; HLA MATCHING; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA REMISSION; LOW DRUG DOSE; LYMPHOCYTE PROLIFERATION; MANTLE CELL LYMPHOMA; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; NONHUMAN; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANIMALS; BONE MARROW TRANSPLANTATION; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; GRAFT REJECTION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MICE;

EID: 78049293282     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/MOH.0b013e32833eaf1b     Document Type: Review

References (47)

1. Appelbaum FR. Hematopoietic-cell transplantation at 50. N Engl J Med 2007; 357:1472-1475.
2. Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373:1550-1561.
3. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol 2002; 128:255-266.
4. Zeiser R, Negrin RS. Interleukin-2 receptor downstream events in regulatory T cells: implications for the choice of immunosuppressive drug therapy. Cell Cycle 2008; 7:458-462.
5. Li Y, Li X, Zheng X, et al. Blocking both signal 1 and signal 2ofT-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999; 5:1298-1302.
6. Luznik L, Jalla S, Engstrom LW, et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 2001; 98:3456-3464.
7. Glucksberg H, Fefer A. Chemotherapy of established graft-versus-host disease in mice. Transplantation 1972; 13:300-305.
8. Owens AH Jr, Santos GW. The effect of cytotoxic drugs on graft-versus-host disease in mice. Transplantation 1971; 11:378-382.
9. Santos GW, Tutschka PJ, Brookmeyer R, et al. Cyclosporine plus methylpred-nisolone versus cyclophosphamide plus methylprednisolone as prophylaxis for graft-versus-host disease: a randomized, double-blind study in patients undergoing allogeneic marrow transplantation. Clin Transplant 1987; 1:21-28.
10. Brodsky RA, Jones RJ. Aplastic anaemia. Lancet 2005; 365:1647-1656.
11. Jones RJ, Barber JP, Vala MS, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood 1995; 85:2742-2746.
12. Luznik L, Engstrom LW, Iannone R, Fuchs EJ. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant 2002; 8:131-138.
13. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J Clin Oncol 1997; 15:1767-1777.
14. Anasetti C, Beatty PG, Storb R, et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990; 29:79-91.
15. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14:641-650.
16. O'Donnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002; 8:377-386.
17. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97:3390-3400.
18. Nomoto K, Eto M, Yanaga K, et al. Interference with cyclophosphamide- induced skin allograft tolerance by cyclosporin A. J Immunol 1992; 149:2668-2674.
19. Fuchs EJ, Luznik L, Bolanos-Meade J, et al. Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT. Bone Marrow Transplant 2009; 43:969-970.
20. Kasamon YL, Luznik L, Leffell MS, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclopho sphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010; 16:482-489.
21. Devetten MP, Hari PN, Carreras J, et al. Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2009; 15:109-117.
22. Kanda Y, Chiba S, Hirai H, et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA-identical siblings over the last decade (1991-2000). Blood 2003; 102:1541-1547.
23. Kasamon YL, Leffell MS, Kowalski J, et al. Greater HLA disparity is associated with reduced risk of relapse and improved event-free survival after nonmyeloablative, HLA-haploidentical BMT with posttransplantation high-dose cyclophosphamide (ASH Annual Meeting Abstracts, November). Blood 2008; 112:150.
24. Bolanos-Meade J, Brodsky RA. Blood and marrow transplantation for sickle cell disease: overcoming barriers to success. Curr Opin Oncol 2009; 21:158-161.
25. Brodsky RA, Luznik L, Bolanos-Meade J, et al. Reduced intensity HLA-haploidentical BMT with post transplantation cyclophosphamide in non-malignant hematologic diseases. Bone Marrow Transplant 2008; 42:523-527.
26. Storb R, Antin JH, Cutler C. Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? Biol Bone Marrow Transplant 2010; 16:S18-S27.
27. Bolwell B, Sobecks R, Pohlman B, et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34:621-625.
28. Cutler C, Li S, Ho VT, et al. Extended follow-up of methotrexate-free im-munosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007; 109:3108-3114.
29. Nash RA, Antin JH, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96:2062-2068.
30. Nash RA, Johnston L, Parker P, et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005; 11:495-505.
31. Ratanatharathorn V, Nash RA, Przepiorka D, et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclos-porine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92:2303-2314.
32. Hahn T, McCarthy PL Jr, Zhang MJ, et al. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 2008; 26:5728-5734.
33. Wagner JE, Thompson JS, Carter SL, Kernan NA. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multicentre, randomised phase II-III trial. Lancet 2005; 366:733-741.
34. Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy.J Clin Oncol 2006; 24:5695-5702.
35. Eapen M, Logan BR, Confer DL, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007; 13:1461-1468.
36. Pavletic SZ, Carter SL, Kernan NA, et al. Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation. Blood 2005; 106:3308-3313.
37. Mielcarek M, Martin PJ, Leisenring W, et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102:756-762.
38. Stewart BL, Storer B, Storek J, et al. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004; 104:3501-3506.
39. Martin PJ, Nash RA. Pitfalls in the design of clinical trials for prevention or treatment of acute graft-versus-host disease. Biol Blood Marrow Transplant 2006; 12:31-36.
40. Bacigalupo A, Lamparelli T, Gualandi F, et al. Increased risk of leukemia relapse with high dose cyclosporine after allogeneic marrow transplantation for acute leukemia: 10 year follow-up of a randomized study. Blood 2001; 98:3174-3175.
41. Bacigalupo A, Van Lint MT, Occhini D, et al. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood 1991; 77:1423-1428.
42. Jenkins MK, Schwartz RH, Pardoll DM. Effects of cyclosporine A on T cell development and clonal deletion. Science 1988; 241:1655-1658.
43. Parkman R. Is chronic graft versus host disease an autoimmune disease? Curr Opin Immunol 1993; 5:800-803.
44. Santos GW, Hess AD, Vogelsang GB. Graft-versus-host reactions and disease. Immunol Rev 1985; 88:169-192.
45. LuznikL, Bolanos-Meade J,ZahurakM, et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010; 115:3224-3230.
46. Durakovic N, Bolaños Meade J, Zahurak M, et al. Secondary systemic immunosuppressants (SSI) after myeloablative HLA matched related and unrelated BMT using HiCy as sole GVHD prophylaxis. Biol Blood Marrow Transplant 2010; 16:S161-S162.
47. Hess AD, Fuchs EJ, LuznikL, et al. Rapid reconstitution of the regulatory T cell compartment after high dose Cy prevents the development of GvHD after allogeneic BMT. Biol Blood Marrow Transplant 2010; 16:S168.